Yamamura D L, Rotstein C, Nicolle L E, Ioannou S
Department of Medicine, McMaster University, Hamilton, Ont.
CMAJ. 1999 Feb 23;160(4):493-9.
Candida species are important bloodstream pathogens that are being isolated with increasing frequency. Despite the availability of effective antifungal therapy, the mortality rate associated with Candida infection remains high. With the objective of describing the epidemiology of candidemia, the Canadian Infectious Disease Society conducted a study of candidemia in Canada.
Fourteen medical centres across Canada identified all patients with candidemia from March 1992 to February 1994 through blood culture surveillance for Candida spp. Patient-related data for invasive fungal infection were compiled retrospectively by chart review using a standardized data-recording form developed for the Fungal Disease Registry of the Canadian Infectious Disease Society. Cases of Candidemia were studied in relation to underlying medical conditions, predisposing factors, concurrent infection, antimicrobial agents, antifungal treatment and deaths.
In total, 415 cases of candidemia were identified, 48 (11.6%) in children and 367 (88.4%) in adults. The causative pathogens were C. albicans in 286 cases (68.9%), C. parapsilosis in 43 (10.4%), C. glabrata in 34 (8.2%), C. tropicalis in 27 (6.5%) and other Candida species in 18 (4.3%); polymicrobial candidemia occurred in 7 cases (1.7%). The overall mortality rate was 46%, and the rate of deaths clinically related to candidemia was 19%. However, only 13 (27%) of the children died. A univariate analysis indicated that significant risk factors for death were age greater than 60 years, therapy for concomitant bacterial infection, stay in an intensive care unit, concurrent malignant disease, cytotoxic chemotherapy and granulocytopenia, although only age and stay in an intensive care unit emerged as significant risk factors in the multivariate analysis. After adjustment for other predictors of death, only infection with C. parapsilosis was associated with a lower mortality rate than infection with C. albicans. Treatment was given in 352 (84.8%) of cases. Amphotericin B was the preferred agent in 244 cases (69.3% of those treated); fluconazole was used in 101 cases (28.7%) and ketoconazole in 5 cases (1.4%).
Candidemia in Canada is caused predominantly by C. albicans. The mortality rate associated with candidemia is high, but it varies with the species of Candida and is lower in children than in adults. Age greater than 60 years and stay in an intensive care unit were the most significant risk factors for overall mortality.
念珠菌属是重要的血流病原体,其分离频率日益增加。尽管有有效的抗真菌治疗方法,但念珠菌感染相关的死亡率仍然很高。为了描述念珠菌血症的流行病学情况,加拿大传染病协会在加拿大开展了一项念珠菌血症研究。
加拿大的14个医疗中心通过对念珠菌属进行血培养监测,确定了1992年3月至1994年2月期间所有念珠菌血症患者。通过使用为加拿大传染病协会真菌疾病登记处开发的标准化数据记录表格,回顾性查阅病历,汇编了与侵袭性真菌感染相关的患者数据。对念珠菌血症病例进行了关于基础疾病、易感因素、合并感染、抗菌药物、抗真菌治疗及死亡情况的研究。
共确定了415例念珠菌血症病例,其中儿童48例(11.6%),成人367例(88.4%)。致病病原体为白色念珠菌286例(68.9%)、近平滑念珠菌43例(10.4%)、光滑念珠菌34例(8.2%)、热带念珠菌27例(6.5%)以及其他念珠菌属18例(4.3%);7例(1.7%)为多微生物念珠菌血症。总体死亡率为46%,临床上与念珠菌血症相关的死亡率为19%。然而,只有13例(27%)儿童死亡。单因素分析表明,死亡的显著危险因素为年龄大于60岁、合并细菌感染的治疗、入住重症监护病房、合并恶性疾病、细胞毒性化疗和粒细胞减少,尽管在多因素分析中只有年龄和入住重症监护病房是显著的危险因素。在对其他死亡预测因素进行调整后,只有近平滑念珠菌感染的死亡率低于白色念珠菌感染。352例(84.8%)病例接受了治疗。两性霉素B是244例(接受治疗者的69.3%)的首选药物;氟康唑用于101例(28.7%),酮康唑用于5例(1.4%)。
加拿大的念珠菌血症主要由白色念珠菌引起。念珠菌血症相关的死亡率很高,但因念珠菌种类而异,儿童的死亡率低于成人。年龄大于60岁和入住重症监护病房是总体死亡率最显著的危险因素。